Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial-Reference-Cited by-同舟云学术

Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial

Published:2006-08-01 Issue:22 Volume:24 Page:3708-3709
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Bonanni Bernardo¹,Macis Debora¹,Maisonneuve Patrick¹,Johansson Harriet A.¹,Gucciardo Giacomo²,Oliviero Pasquale³,Travaglini Roberto⁴,Muraca Maria G.⁵,Rotmensz Nicole¹,Veronesi Umberto¹,Decensi Andrea U.⁶

Affiliation:

1. European Institute of Oncology, Milan, Italy

2. Ospedale San Camillo Forlanini, Rome, Italy

3. Fondazione Pascale, Naples, Italy

4. Fondazione Maugeri, Pavia, Italy

5. Centro per lo Studio e la Prevenzione Oncologica, Florence, Italy

6. European Institute of Oncology, Milan; and Ente Ospedaliero Ospedali Galliera, Genoa, Italy

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.06.8072

Reference1 articles.

1. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of CYP2D6 polymorphisms on the efficacy of tamoxifen in Iraqi women with breast cancer;Journal of Contemporary Medical Sciences;2023-12-26

2. Explore the distribution of (rs35742686, rs3892097 and rs1065852) genetic polymorphisms of cytochrome P4502D6 gene in the Moroccan population;Egyptian Journal of Medical Human Genetics;2022-11-21

3. Pharmacogenetics of Drugs Used in the Treatment of Cancers;Genes;2022-02-07

4. CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial;Annals of Oncology;2021-10

5. Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics;Expert Opinion on Drug Metabolism & Toxicology;2020-12-29